American Heart Association – 2023 (Philadelphia)

LBCT Presentations

Christian Ruff – AZALEA-TIMI 71-A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab Compared with Open-Label Rivaroxaban in Patients with Atrial Fibrillation

Other Presentations

Khaled Abdelrahman – Cardiometabolic Risk Factors and Non-Culprit Plaque Characteristics in Patients with STEMI in REAL-TIMI 63B  

John Bertot – Predictive Utility Of A CAD Polygenic Risk Score In A Low-Risk Primary Prevention Cohort

Marc Bonaca – Stem Cell Factor Associated with Critical Limb Ischemia in Patients with Peripheral Artery Disease

Anthony Carnicelli – Characteristics and Outcomes of Patients with Clinically Significant Valvular Heart Disease

Christine Chow – Association of Hemoglobin with In-Hospital Mortality in Patients Admitted to the Cardiac Intensive Care Unit Data from the CCCTN Registry

Prakriti Gaba – Association Between Achieved LDL-Cholesterol Levels and Long-term Cardiovascular and Safety Outcomes-An Analysis of FOURIER-OLE

Prakriti Gaba – Intraindividual Variability in Serial Lipoprotein(a) Concentrations among Placebo-Treated Patients in the OCEAN(a)-DOSE Trial

Ameesh Isath – MICU Overflow Patients in the Cardiac Intensive Care Unit – Insights from the Critical Care Cardiology Trials Network Registry

Danny McClintick – Long-Term Efficacy of Evolocumab in Patients with and without Multi-Vessel Disease

Sachit Singal – CAD Polygenic Risk Score and Incident Complex Coronary Revascularization In Adults with Atherosclerosis

Sachit Singal – Modes of In-Hospital Death In Patients with Cardiogenic Shock – An Analysis from the Critical Care Cardiology Trials Network

Stephanie Skove – Early Evolution of SCAI Shock Stage and In-Hospital Mortality in a CICU Population from the Critical Care Cardiology Trials Network (CCCTN)

Andre Zimerman – Performance of a Polygenic Risk Score for CAD Across the Spectrum of ASCVD-An Analysis of 60k Patients from 6 TIMI Randomized Trials

Andre Zimerman – Long-Term Neurocognitive Safety of LDL-C Lowering with Evolocumab-Open-Label Extension Data from FOURIER



%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close